Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch
Pills and a daily pill organizer: Arbli’s liquid formulation helps patients who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwideglobenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to nearly 95 cents” on the newsragingbull.com. By mid-day, Reuters reported SCNX trading near $0.71, up ~30% from the prior closereuters.com.